Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Eptifibatide treatment reduces incidence of death in acute myocardial infarction and unstable angina

Aug. 25, 1998

Corvas and Schering-Plough discontinue collaboration; other projects remain on track

Aug. 24, 1998

Novel antithrombotic agents added to the pipeline at NicOx

Aug. 17, 1998

Zeneca claims factor Xa inhibitors with antithrombotic/anticoagulant activity

Aug. 17, 1998

First volunteers dosed with R.W. Johnson's new gpIIb/IIIa antagonist

Aug. 14, 1998

NQ-304, a novel platelet antiaggregatory and antithrombotic agent in early development

Aug. 12, 1998

New antiplatelet agent, PDE III inhibitor, reported by Taiwanese scientists

Aug. 11, 1998

Roberts receives permission to launch Agrylin in Israel

Aug. 10, 1998

Predictors of vascular access site complications during angioplasty with eptifibatide

July 31, 1998

Ibex suspends phase III trial of Neutralase pending further analysis of data

July 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...